Literature DB >> 29635884

Deposition of inhaled nanoparticles is reduced in subjects with COPD and correlates with the extent of emphysema: proof of concept for a novel diagnostic technique.

H L Aaltonen1,2, J K Jakobsson3, S Diaz1,2, S Zackrisson1,2, E Piitulainen4, J Löndahl3, P Wollmer1,2.   

Abstract

BACKGROUND: The diagnosis of chronic obstructive pulmonary disease (COPD) is often based on spirometry, which is not sensitive to early emphysema. We have recently described a method for assessing distal airspace dimensions by measuring recovery of nanoparticles in exhaled air after a single-breath inhalation followed by breath-hold. Recovery refers to the non-deposited particle fraction. The aim of this study was to explore differences in the recovery of exhaled nanoparticles in subjects with COPD and never-smoking controls. A secondary aim was to determine whether recovery correlates with the extent of emphysema.
METHOD: A total of 19 patients with COPD and 19 controls underwent three repeats of single-breath nanoparticle inhalation followed by breath-hold. Particle concentrations in the inhaled aerosol, and in an alveolar sample exhaled after breath-hold, were measured to obtain recovery.
FINDINGS: The patients with COPD had a significantly higher mean recovery than controls, 0·128 ± 0·063 versus 0·074 ± 0·058; P = 0·010. Also, recovery correlated significantly with computed tomography (CT) densitometry variables (P<0·01) and diffusing capacity for carbon monoxide (DL,CO ; P = 0·002).
INTERPRETATION: Higher recovery for emphysema patients, relative to controls, is explained by larger diffusion distances in enlarged distal airspaces. The nanoparticle inhalation method shows potential to be developed towards a tool to diagnose emphysema.
© 2018 The Authors. Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine.

Entities:  

Keywords:  AiDA; COPD; CT densitometry; emphysema; nanoparticles; respiratory diagnostics

Year:  2018        PMID: 29635884     DOI: 10.1111/cpf.12517

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  6 in total

1.  Airspace Dimension Assessment with Nanoparticles (AiDA) in Comparison to Established Pulmonary Function Tests.

Authors:  Madeleine Petersson-Sjögren; Jonas Jakobsson; H Laura Aaltonen; Hanna Nicklasson; Jenny Rissler; Gunnar Engström; Per Wollmer; Jakob Löndahl
Journal:  Int J Nanomedicine       Date:  2022-06-25

2.  Airspace Dimension Assessment (AiDA) by inhaled nanoparticles: benchmarking with hyperpolarised 129Xe diffusion-weighted lung MRI.

Authors:  Madeleine Petersson-Sjögren; Ho-Fung Chan; Guilhem J Collier; Graham Norquay; Lars E Olsson; Per Wollmer; Jakob Löndahl; Jim M Wild
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

Review 3.  Aerosolised micro and nanoparticle: formulation and delivery method for lung imaging.

Authors:  Miftakul Munir; Herlan Setiawan; Rohadi Awaludin; Vicky L Kett
Journal:  Clin Transl Imaging       Date:  2022-09-29

4.  Airspace Dimension Assessment with nanoparticles reflects lung density as quantified by MRI.

Authors:  H Laura Aaltonen; Simon S Kindvall; Jonas K Jakobsson; Jakob Löndahl; Lars E Olsson; Sandra Diaz; Sophia Zackrisson; Per Wollmer
Journal:  Int J Nanomedicine       Date:  2018-05-21

5.  Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease.

Authors:  Jonas K F Jakobsson; H Laura Aaltonen; Hanna Nicklasson; Anders Gudmundsson; Jenny Rissler; Per Wollmer; Jakob Löndahl
Journal:  BMC Pulm Med       Date:  2018-08-06       Impact factor: 3.317

6.  Airspace dimension assessment with nanoparticles as a proposed biomarker for emphysema.

Authors:  H Laura Aaltonen; Madeleine Petersson Sjögren; Jonas K F Jakobsson; Hanna Nicklasson; Sandra Diaz; Francisco Sánchez Montiel; Sophia Zackrisson; Veronica Ideböhn; Gunnar Engström; Jakob Löndahl; Per Wollmer
Journal:  Thorax       Date:  2021-04-15       Impact factor: 9.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.